Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor


  • Sameer Dhingra School of Pharmacy, Faculty of Medical Sciences, Eric Williams Medical Sciences Complex, Mount Hope Campus, The University of the West Indies, St. Augustine, Trinidad and Tobago
  • Mamta Sachdeva University Institute of Pharmaceutical Sciences, UGC Center of Advanced Study (UGC-CAS) in Pharmaceutical Sciences, Panjab University, Chandigarh-160 014, India


Mantle cell lymphoma, BTK-inhibitor, B-cell antigen receptor, Ibrutinib


Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with short remission duration to standard therapies and a median overall survival of 4–5 years. Small molecule inhibitors targeting dysregulated pathways (MAPK/ERK, PI3K/PKB/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in clinical trials, recently been approved by FDA in the treatment of MCL. 


Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012; 87(6):604-9.

Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol 2012; 5(1):31.

Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath S, Liu D. Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol 2012; 5(1):21.

Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol 2012; 5(1):3.

WeiSZ L, Efferth T. Polo-like kinase 1 as target for cancer therapy. Exp J Hematol Oncol 2012; 1(1):38.

McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8):2825–2833.

Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97(1):101–106.

Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012; 5:64.

Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp J Hematol Oncol 2012, 1(1):36.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117(23):6287–6296.

Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5(4):251–262.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107(29):13075–13080.

Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013; 6:59

National Cancer Institute at the National Institutes of Health. Available at http://www.cancer.gov/drugdictionary?cdrid=638648. Accessed 15 July 2013.

Betty Y. Chang, Michelle Francesco, Martin F.M. De Rooij, et al. Egress of CD19+ CD5+ cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013; 02-482125.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369:32-42.

Advani RH, Joseph JB, Jeff PS, Sonali MS, Thomas EB, Barbara G, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31:88-94.

Chavez JC, Eva S, Javier PI. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core evidence 2013; 8: 37.

U.S. FDA. Available at http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm. Last accessed November 30, 2013.

U.S. FDA. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205552lbl.pdf.





How to Cite

Dhingra, S., & Sachdeva, M. (2017). Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor. International Journal of Basic & Clinical Pharmacology, 3(1), 249–254. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/991



New Drug Update